Itching of the skin
Conditions
Interventions
Nemolizumab (CD14152) or placebo will be provided as lyophilized powder for
solution for subcutaneous injection only after reconstitution in a single-use,
pre-filled, dual-chamber syringe (DCS).
Dur
Sponsors
Galderma
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Male or female and aged >=18 years at the time of screening; 2. Clinical diagnosis of PN for at least 6 months with: a. Pruriginous nodular lesions on upper limbs, trunk, and/or lower limbs; b. At least 20 nodules on the entire body with a bilateral distribution c. IGA score >= 3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate and 4 is severe) at both the screening and baseline visits; 3. Severe pruritus defined as follows on the PP NRS: • At the screening visit (Visit 1): PP NRS score is >= 7.0 for the 24-hour period immediately preceding the screening visit; • At the baseline visit (Visit 2): Mean of the daily intensity of the PP NRS score is >= 7.0 over the previous week; 4. Female subjects of childbearing potential (ie, fertile, following menarche and until becoming post-menopausal unless permanently sterile) must agree to use at least 1 adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection. Adequate and approved methods of contraception applicable for the subject and/or her partner are defined below: • True abstinence, when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception; • Progestogen-only oral hormonal contraception; • Combination of male condom with cap, diaphragm, or sponge with spermicide (double barrier methods); • Combined (estrogen- and progestogen-containing) oral, intravaginal, or transdermal hormonal contraception; • Injectable or implanted hormonal contraception; • Intrauterine devices or intrauterine hormone releasing system; • Bilateral tubal ligation or tube insert (such as the Essure system) at least 3 months before the study; • Vasectomy of male partner at least 3 months before the study 5. Female subjects of non-childbearing potential must meet 1 of the following criteria: • Absence of menstrual bleeding for 1 year prior to screening without any other medical reason; • Documented hysterectomy , bilateral salpingectomy, or bilateral oophorectomy at least 3 months before the study; 6. Subject is willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol, including daily diary recordings by the subject using an electronic handheld device provided for this study. 7. Read, understood and signed an informed consent form (ICF) before any investigational procedure(s) are performed.
Exclusion criteria
Exclusion criteria: 1. Body weight < 30 kg; 2. Chronic pruritus resulting from another active condition other than PN, such as but not limited to scabies, lichen simplex chronicus, psoriasis, atopic dermatitis, contact dermatitis, acne, folliculitis, lichen planus, habitual picking/excoriation disorder, sporotrichosis, bullous autoimmune disease, end-stage renal disease, cholestatic liver disease (eg, primary biliary cirrhosis) , or diabetes mellitus or thyroid disease that is not adequately treated, as per standard of care; 3. Unilateral lesions of prurigo (eg, only one arm affected); 4. History of or current confounding skin condition (eg, Netherton syndrome, cutaneous T-cell lymphoma [mycosis fungoides or Sezary syndrome], chronic actinic dermatitis, dermatitis herpetiformis) 5. Subjects meeting 1 or more of the following criteria at screening or baseline: - Had an exacerbation of asthma requiring hospitalization in the preceding 12 months; - Reporting asthma that has not been well-controlled (ie, symptoms occurring on <; 2 days per week, nighttime awakenings 2 or more times per week, or some interference with normal activities) during the preceding 3 months; - Asthma Control Test <= 19 (only for subjects with a history of asthma) - Peak expiratory flow < 80% of the predicted value. 6. Subjects with a current medical history of chronic obstructive pulmonary disease and/or chronic bronchitis; 7. Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit. Subjects may be rescreened once the infection has resolved. . Resolution of COVID-19 infection can be confirmed by recovery assessment methods, as described in Section 8.4.2.; 8. Positive serology results (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb], hepatitis C antibody, or human immunodeficiency virus antibody) at the screening visit; 9. Requiring rescue therapy for PN during the screening period or expected to require rescue therapy within 4 weeks following the baseline visit; 10. Subjects with active atopic dermatitis (signs and symptoms other than dry skin) in the last 3 months; 11. Neuropathic and psychogenic pruritus such as but not limited to notalgia paresthetica, brachioradial pruritus, small fiber neuropathy, skin picking syndrome, or delusional parasitosis; 12. Having received any of the treatments in the table reported in the protocol within the specified timeframe before the baseline visit; 13. Previous participation in a clinical study with nemolizumab; 14. Pregnant women (positive serum pregnancy test result at the screening visit or positive urine pregnancy test at the baseline visit), breastfeeding women, or women planning a pregnancy during the clinical study; 15. History of lymphoproliferative disease or history of malignancy of any organ system within the last 5 years, except for: - Basal cell carcinoma, squamous cell carcinoma in situ (Bowen*s disease), or carcinomas in situ of the cervix that have been treated and have no evidence of recurrence in the last 12 weeks before the screening vis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoints: * Proportion of subjects with an improvement of >= 4 from baseline in Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16 * Proportion of subjects with an Investigator Global Assessment (IGA) success (defined as an IGA of 0 [Clear] or 1 [Almost clear] and a >= 2- point improvement from baseline) at Week 16 | — |
Secondary
| Measure | Time frame |
|---|---|
| Key secondary endpoints: * Proportion of subjects with an improvement of >= 4 from baseline in PP NRS at Week 4 * Proportion of subjects with PP NRS = 4 from baseline in SD NRS at Week 16 * Proportion of subjects with an improvement of >= 4 from baseline in SD NRS at Week 4 * Proportion of subjects with PP NRS | — |
Countries
Netherlands
Outcome results
None listed